Apimeds Pharmaceuticals US, Inc. acquired 100% of the Apitox rights for Korean medicine clinics and a 25% Royalty on U.S. proceeds from FreeT. This Acquisition enhances Apimeds’ commercial prospects in a growing market.
Key Highlights
- Apimeds Pharmaceuticals secured 100% rights to the Apitox market in Korea through a new agreement with FreeT.
- The agreement grants Apimeds a 25% royalty on U.S. commercialization Revenue from Apitox.
- FreeT confirmed its support for Apimeds in future global Apitox transactions beyond the United States.
This development, finalized on August 19, 2026, positions Apimeds to Capitalize on the growing Demand for Apitox in Korea, particularly in specialized clinical settings. As part of the assignment agreement with FreeT Inc. Apimeds Pharmaceuticals US, Inc. (AMEX: APUS) has secured one hundred percent (100%) of the rights originally acquired by FreeT under a prior agreement dating back to 2015. This substantial shift marks a significant milestone for Apimeds as it expands its operational footprint in the pharmaceutical sector and enhances its potential for revenue generation in a burgeoning market.
Details of the Agreement
The assignment agreement includes a multifaceted transfer of rights that not only encompasses the exclusive Apitox market rights in Korea, but also grants Apimeds a 25% royalty entitlement on the economic proceeds from any development, licensing, or sale of Apitox within the United States. This significant royalty structure could prove instrumental in augmenting the company’s revenue stream as it focuses on bringing new therapeutic Options to market. Apimeds will receive quarterly progress updates on clinical efforts and overseas transactions related to Apitox, ensuring that it remains well-informed about the product's development trajectory.
This access to real-time information can enhance strategic decision-making as the company pursues further growth opportunities.
Implications for Apimeds
The acquisition of these rights from FreeT cements Apimeds’ position in the competitive pharmaceutical environment, particularly within the area of Korean medicine where Apitox is expected to increase in relevance. FreeT, as the successor to CNP Roen Co. Ltd. has implied strong support for Apimeds in further developing and commercializing Apitox, indicating a commitment to a collaborative relationship. The grant of explicit participation rights in revenue from overseas rights agreements adds another layer of potential profit for Apimeds.
Such rights can provide a pathway for future partnerships and licensing deals, ultimately expanding the reach of Apitox beyond its current markets.
Future Developments
Looking ahead, Apimeds’ newly acquired rights could facilitate comprehensive exploration for further territories outside the U.S. dependent on future agreements with FreeT. The assignment clearly stipulates FreeT's intention to assist in the ongoing development of Apitox, with potential expansions that may Leverage Apimeds' expertise. Apimeds must navigate the complex regulatory environment tied to these rights, as the agreement is governed under Korear law, establishing Seoul Central District Court as the exclusive Jurisdiction for disputes.
Stakeholders will be keenly observing how Apimeds maneuvers through these upcoming phases and the execution of additional rights agreements, which could markedly influence its market positioning.
Peers Moving on This News
- Alzamend Neuro, Inc. (NASDAQ: ALZN) down 0.6%
- Ensysce Biosciences, Inc. (NASDAQ: ENSC) down 2.0%



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...